Status:
COMPLETED
Yellow Fever Immune Response at Single Cell Resolution
Lead Sponsor:
Rockefeller University
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Healthy
Eligibility:
All Genders
18-59 years
Brief Summary
The immune system is composed of diverse cell types with different functions that act together in order to defend against infection. This pilot study will test a new technology for studying these many...
Detailed Description
Vaccines have had monumental impact in reducing the mortality and morbidity of infectious disease. However, the underlying immune mechanisms that contribute to their effectiveness are incompletely und...
Eligibility Criteria
Inclusion
- Male or female between the ages of 18 and 59 years old
- Volunteers who have not received a vaccination within 30 days of the YFV and do not anticipate to receive a vaccination within 30 days
- Volunteers who are seeking the YFV for either travel reasons or occupational risk
- Volunteers willing to undergo one screening visit, one visit to receive the YFV, and four post-vaccination visits
- Volunteers without medical conditions who are willing to give blood once for the development of the inDrop technique
Exclusion
- Male or females under 18 or over 59 years of age
- Volunteers who received other vaccination less than 30 days prior to receiving the YFV
- Volunteers with acute or febrile disease
- Volunteers unable to return for the post vaccination follow-up visits
- Volunteers with an allergy to eggs, chicken proteins, gelatin, or other components of the Yellow Fever vaccine
- Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study
- Is pregnant or lactating
- Volunteers with a history of yellow fever vaccination and/or infection
- Volunteers with a history of viral hepatitis and/or non-viral liver disease
- In the opinion of the investigators, the volunteer is unlikely to comply with the study protocol
- Immunosuppressed individuals as a result of cancer, transplantation, and or primary immunodeficiency
- Immunosuppressed individuals as a result of medications (such as high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF-α inhibitors (e.g., etanercept), IL-1 blocking agents (e.g., anakinra), and other monoclonal antibodies targeting immune cells (e.g.,rituximab, alemtuzumab) and/or radiation
- Volunteers with thymus disorders (including myasthenia gravis, Di George syndrome, or thymoma) and/or history of thymectomy
- Individuals infected with HIV
Key Trial Info
Start Date :
August 22 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 5 2018
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03458780
Start Date
August 22 2016
End Date
September 5 2018
Last Update
November 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Rockefeller University
New York, New York, United States, 10065